What is Cardiff Oncology, Inc.'s (CRDF) StockRank?

MoatMap's StockRank for Cardiff Oncology, Inc. (CRDF) is 2/100, with a Strong Sell signal. This is a composite score combining Quality (23), Value (33), and Momentum (14) factor ranks across MoatMap's 20,000+ stock universe.

Does Cardiff Oncology, Inc. have an economic moat?

Cardiff Oncology, Inc. (CRDF) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Cardiff Oncology, Inc. a buy, hold, or sell?

MoatMap's current signal for Cardiff Oncology, Inc. (CRDF) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Cardiff Oncology, Inc. in?

Cardiff Oncology, Inc. (CRDF) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CRDF

STRONG SELLREMOVE

Cardiff Oncology, Inc. · Healthcare · United States · $126M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-84.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Cardiff Oncology is a clinical-stage biotech with high cash burn and no commercialized products. It does not fit our CDMO pricing power theme, which requires validated, high-utilization manufacturing assets rather than speculative drug pipelines.

COMPANY DESCRIPTION

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer patients by targeting the PLK1 enzyme pathway. Its proprietary small molecule drug candidate (onvansertib) with a specific mechanism of action targets key cancer pathways, potentially addressing unmet needs in various solid and liquid tumors. Cardiff Oncology is a specialized oncology biotechnology firm advancing novel therapeutic candidates for difficult-to-treat cancers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	386,000	488,000	683,000	593,000	15.4%
EPS	-0.89	-0.93	-0.95	-0.69	—
Shares	45M	45M	67M	68M	+52.9%
Debt	3M	2M	2M	832,000	-32.6%
Equity	106M	70M	83M	45M	-24.7%
Op CF	-34M	-31M	-38M	-38M	—
Inv CF	38M	36M	14M	1M	—
Fin CF	75,000	0	54M	3M	—

PRICE (1M)-29.8%

SMA 50SMA 200

$1.18

RSI (14)

26.8

52W High

$4.56

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-107.6%4.8

ROE

-84.8%9.4

GP/Assets

-50.2%1.2

Op. Margin

-31341.5%1.1

FCF/Assets

-32.4%7.9

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.02x83.3

Current Ratio

3.27x57.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.3x65.2

P/FCF

—N/A

P/B

3.0x39.1

P/S

200.6x5.2

Div Yield

—N/A

Momentum

52W High %

26%4.1

RS 6M

-61%17.9

SMA 50/200

0.81x14.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-21%14.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$126M

P/E (Forward)

-1.9x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRDF are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CRDF	Cardiff Oncology, Inc.(you)	$126M	2	STRONG SELL
NTHI	NeOnc Technologies Holdings, Inc.	$125M	1	STRONG SELL
GNLX	Genelux Corporation	$138M	2	STRONG SELL
CBUS	Cibus, Inc.	$117M	3	STRONG SELL
KLRS	Kalaris Therapeutics, Inc.	$123M	4	STRONG SELL
INO	Inovio Pharmaceuticals, Inc.	$107M	0	STRONG SELL
KALA	KALA BIO, Inc.	$104M	2	STRONG SELL
2592.HK	Cloudbreak Pharma Inc.	$140M	5	STRONG SELL
GALT	Galectin Therapeutics Inc.	$169M	1	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	5	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Cardiff Oncology, Inc. (CRDF) — Stock Score Summary

Cardiff Oncology, Inc. (CRDF) has a MoatMap StockRank of 2/100 based on Quality (23/100), Value (33/100), and Momentum (14/100) factor scores. The current signal is STRONG SELL. Cardiff Oncology is a clinical-stage biotech with high cash burn and no commercialized products. It does not fit our CDMO pricing power theme, which requires validated, high-utilization manufacturing assets rather than speculative drug pipelines.

Key Financial Metrics

Price	$1.18
Market Cap	$126M
P/E (Forward)	-1.90
Price/Book	3.03
Return on Equity	-84.8%
Return on Invested Capital	-107.6%
Debt/Equity	1.86
Gross Margin	0.0%
Operating Margin	-31341.5%
Revenue Growth	-62.4%
Free Cash Flow	$-20M

Cardiff Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Cardiff Oncology, Inc.’s (CRDF) StockRank?: MoatMap’s StockRank for Cardiff Oncology, Inc. (CRDF) is 2/100, with a Strong Sell signal. It is a composite of Quality (23), Value (33), and Momentum (14) factor ranks across MoatMap’s 20,000+ stock universe.
Does Cardiff Oncology, Inc. have an economic moat?: Cardiff Oncology, Inc. (CRDF) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cardiff Oncology, Inc. a buy, hold, or sell?: MoatMap’s current signal for Cardiff Oncology, Inc. (CRDF) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cardiff Oncology, Inc. in?: Cardiff Oncology, Inc. (CRDF) operates in the Healthcare sector, specifically the Biotechnology industry (United States).